MedTrace Logo

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

NCT00180921 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-09-26

No results posted yet for this study

Summary

This is a Phase II study of imatinib (Glivec) administered as a daily oral treatment in patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.

Conditions

  • Cancer of the Head and Neck
  • Carcinoma, Adenoid Cystic

Interventions

DRUG

Imatinib

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Sandrine Faivre, MD · Centre Hospitalier de Beaujon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180921 on ClinicalTrials.gov